Greater Cannabis Company Reiterates Going Concern Amid Dire Q1 Financials; Restates Prior Quarter

summarizeSummary

Greater Cannabis Company's Q1 2026 report confirms severe financial distress with critically low cash and ongoing losses, reiterating going concern doubts, and discloses a restatement of prior financials.

check_boxKey Events

• Severe Financial Distress Continues

  The company reported critically low cash of $1,439, negative working capital of $775,025, and a net loss of $33,376 for Q1 2026, reinforcing substantial doubt about its ability to continue as a going concern through March 2027.

• Prior Financials Restated

  The company restated its Q1 2025 financial statements to correct terms of a note agreement, initially involving $138,906 in default penalties and interest, which were subsequently waived in Q2 2025.

• Clinical Trial Stalled

  The Phase II Clinical Trial for its cannabinoid therapeutic is delayed due to the inability to source specialized active pharmaceutical ingredients (API) and the need for additional funding.

auto_awesomeAnalysis

This quarterly report confirms the company's severe financial distress, reiterating substantial doubt about its ability to continue as a going concern, a situation previously disclosed in its March 31, 2026 10-K. The updated Q1 2026 financials show critically low cash reserves of $1,439 and persistent negative working capital, highlighting the urgent need for additional funding. Furthermore, the company restated its Q1 2025 financials due to errors in a note agreement, although associated penalties were later waived. Delays in its Phase II clinical trial due to API sourcing and funding needs add to the operational challenges.